No results for ‘’
Torrent Pharmaceuticals Ltd
₹4429.80
(0.35%)
Fri, 26 Jun 2026, 01:41 am
Health Technology
Pharmaceuticals: Major
24.5KTorrent Pharmaceuticals Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 32.77 | 17.85 | 8.88 | 6.15 | 19.95 | 18.11 | 18.73 | 13.59 | 13.35 | 26.16 | 13.08 | 28.08 | 31.14 | 75.72 | 32.56 | 34.35 | 60.89 | 41.78 | 53.15 | 57.28 |
| Price to book ratio | 5.29 | 4.07 | 2.35 | 1.74 | 5.55 | 4.82 | 4.48 | 4.16 | 4.67 | 7.89 | 6.49 | 6.03 | 4.57 | 6.99 | 6.92 | 7.37 | 7.95 | 8.39 | 12.84 | 14.42 |
| Price to sales ratio | 1.97 | 1.32 | 0.91 | 0.72 | 2.52 | 2.31 | 2.05 | 1.93 | 2.20 | 4.30 | 3.46 | 4.57 | 3.57 | 4.35 | 4.25 | 5.41 | 5.58 | 5.46 | 8.30 | 9.64 |
| Price to cash flow ratio | 83.94 | 29.84 | 5.38 | 4.54 | 16.94 | 12.55 | 10.50 | 37.63 | 15.54 | 31.01 | 8.94 | 31.87 | 33.81 | 25.36 | 36.09 | 25.99 | 30.48 | 25.04 | 30.27 | 46.72 |
| Enterprise value | 2022Cr | 1947Cr | 1443Cr | 1392Cr | 4762Cr | 4880Cr | 5103Cr | 5830Cr | 8968Cr | 21274Cr | 23546Cr | 26759Cr | 26097Cr | 37880Cr | 38536Cr | 47134Cr | 50802Cr | 56672Cr | 91077Cr | 112000Cr |
| Enterprise value to EBITDA ratio | 26.58 | 15.60 | 8.66 | 5.40 | 13.78 | 15.96 | 11.29 | 10.57 | 9.51 | 21.46 | 8.52 | 20.02 | 19.65 | 19.36 | 17.86 | 18.94 | 21 | 20.13 | 27.36 | 30.73 |
| Debt to equity ratio | 0.76 | 0.73 | 0.72 | 0.75 | 0.65 | 0.58 | 0.49 | 0.49 | 0.60 | 1.10 | 0.67 | 0.58 | 1.40 | 1.28 | 1.21 | 0.84 | 0.68 | 0.87 | 0.59 | 0.42 |
| Return on equity % | 16.95 | 24.67 | 29.28 | 31.78 | 31.20 | 29.25 | 25.78 | 33.25 | 40.09 | 34.24 | 57.92 | 23.80 | 15.12 | 9.34 | 21.47 | 23.49 | 13.18 | 20.50 | 25.38 | 26.46 |
Torrent Pharmaceuticals Ltd Price to Sales Ratio
The Torrent Pharmaceuticals Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Torrent Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Torrent Pharmaceuticals Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM, BSE: 500420) is currently trading at ₹4429.80, with a market capitalization of ₹150360.2Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Torrent Pharmaceuticals Ltd Price to Sales Ratio is essential for fundamental analysis.
Torrent Pharmaceuticals Ltd Price to Sales Ratio Current Value
The current Torrent Pharmaceuticals Ltd Price to Sales Ratio stands at 9.64.
The latest Torrent Pharmaceuticals Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Torrent Pharmaceuticals Ltd Price to Sales Ratio Historical Trend
The Torrent Pharmaceuticals Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 9.64
- 2023: 8.30
- 2022: 5.46
- 2021: 5.58
- 2020: 5.41
The recent rise in Torrent Pharmaceuticals Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.
What Torrent Pharmaceuticals Ltd Price to Sales Ratio Indicates for Investors
The Torrent Pharmaceuticals Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Torrent Pharmaceuticals Ltd Price to Sales Ratio Analysis Summary
The Torrent Pharmaceuticals Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Torrent Pharmaceuticals Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Torrent Pharmaceuticals Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.